Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
